Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer — Stella

Home/Lung Cancer Metastatic/

View on ClinicalTrials.gov

Recruiting

Back to Lung Cancer Metastatic trials

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

United States

University of California, San Francisco, San Francisco, California

Key details

Phase

Early testing

Sponsor

Collin Blakely

Collaborators

Puma Biotechnology, Inc.

Enrollment target

~38 participants

Started

November 2019

Primary completion

December 2026

Age range

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

18 Years and older

Last updated June 2024